Navigation Links
Anesiva Announces Second Quarter 2008 Financial Results and Update

SOUTH SAN FRANCISCO, Calif., Aug. 7 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today reported financial results and accomplishments for the second quarter and six months ended June 30, 2008.

"The 2008 second quarter marked a significant advance for Anesiva as we introduced Zingo(TM) in the U.S. pediatric hospital market," said Michael L. Kranda, president and chief executive officer. "In addition, I'm pleased to report that our Phase 3 trials of Adlea(TM) for the management of acute pain following total knee replacement surgeries and bunionectomy surgeries are nearing full patient enrollment. As a result, we anticipate releasing top-line data from both trials in the fourth quarter of this year."

"While we continue to make progress in our current commercial and clinical initiatives, I am conducting a full strategic review of the company's programs, timelines and resource allocations," Mr. Kranda said. "Based on the results of this evaluation, in early September I intend to present a comprehensive forward-looking plan for Anesiva's growth as a company focused on the late-stage development and commercialization of novel products that address unmet needs in the treatment of pain." Mr. Kranda was appointed Anesiva's president, chief executive officer and member of the board of directors in June 2008.

Second Quarter 2008 Financial Results

Total operating expenses in the second quarter of 2008 were $22.1 million, including $1.6 million in non-cash stock-based compensation, compared to total operating expenses of $14.7 million, including $2.4 million in non-cash stock- based compensation, in the second quarter of 2007. For the six months ended June 30, 2008, total operating expenses were $43.9 million compared to $27.4 million for the six months ended June 30, 2007, and include $3.2 million and $4.5 million in non-cash stock-based compensation in the 2008 and 2007 periods, respectively.

Operating expenses during the quarter primarily related to the continued development and commercial preparations to launch, Zingo, a fast-acting, needle-free, local anesthetic, for the pediatric indication. Additional operating expenses related to the ongoing development of Adlea, which is being evaluated in Phase 3 trials for the treatment of acute pain following total knee replacement surgeries and bunionectomy surgeries.

For the second quarter of 2008, the net loss was $21.9 million, or $0.54 per share. In the second quarter of 2007, the net loss was $13.8 million, or $0.51 per share. The net loss for the six months ended June 30, 2008 was $43.4 million, or $1.08 per share, and for the six months ended June 30, 2007, the net loss was $25.5 million or $0.93 per share.

As of June 30, 2008, cash, cash equivalents and investments were $48.7 million compared to $90.8 million at December 31, 2007. The company believes it has sufficient resources to fund anticipated expenses for the remainder of 2008 and into 2009.

Commercial and Product Development Updates:


-- Following the Zingo U.S. commercial launch in late June, Anesiva began

supplying hospitals in its target pediatric market. The early phase of

the Zingo launch is focused on supporting initial product experiences

and formulary review and acceptance processes in these institutions.

Commenting on the initial Zingo launch, Nancy E. Donahue, senior vice president, sales and marketing, said, "While it is too early to provide meaningful sales metrics as we are just six weeks into the launch, initial qualitative feedback from healthcare providers who have used Zingo suggests that they are very pleased with its performance and ease of use. We continue to conduct training sessions for selected healthcare providers to advocate for better venous access pain management for their pediatric patients, to grow membership in RNVoice, and to experience increased visits to"

-- The FDA accepted Anesiva's electronic sNDA filing to expand the Zingo

label indication to include adults. Under the Prescription Drug User

Fee Act (PDUFA), the agency is expected to make a decision regarding

approval by January 2009.

-- The journal Pediatrics published full results of one of the two pivotal

Phase 3 pediatric trials of Zingo.

-- Anesiva signed an exclusive Zingo licensing and distribution agreement

with Green Vision Company for territories in the Middle East, and

expanded the territories covered under the license and distribution

agreement with Sigma Tau SpA to include most of Europe.


-- During the second quarter, Phase 3 enrollment began in a trial of Adlea

for the management of acute pain following total knee replacement

surgery. This multicenter, double-blind, placebo-controlled study will

evaluate the efficacy and safety of a single dose of Adlea or placebo

administered prior to closure of the surgical wound. Total planned

enrollment is 214 patients. Enrollment continued in a 300 patient Phase

3 trial of Adlea in patients undergoing bunionectomy surgery.

-- Anesiva initiated a Phase 2 trial with Adlea for the management of

acute pain following arthroscopic shoulder surgery. Total planned

enrollment in this multicenter, double-blind, dose-escalation, placebo-

controlled trial is 74 patients.

-- Several Adlea posters will be presented at the upcoming World Congress

on Pain, a major international meeting to be held August 17-22, 2008.

Studies to be presented will include:

* A Phase 2, 185-patient randomized, placebo-controlled, dose-

escalation study in bunionectomy surgeries, which demonstrated

statistically significant reductions in average and worst pain scores

in the 1 mg Adlea dose group compared to placebo. In addition,

patients in the 1 mg Adlea group had a statistically significantly

longer median time to first use of an opioid or another acute pain

treatment compared to placebo. This Phase 2 trial is the basis for

the ongoing Phase 3 Adlea trial in bunionectomy surgeries, which

compares the same 1 mg Adlea dose to placebo control; the primary

endpoint in both trials is reduction in pain up to 32 hours post-

surgery for Adlea versus placebo.

* An exploratory clinical study in painful osteoarthritis of the knee

in which Adlea was generally well-tolerated, particularly when

stepwise dosing was used to reduce pain on injection in this non-

surgical setting. The study also generated longer-term data

suggesting reduced pain scores compared to baseline for up to the

eight week study endpoint.

* An independent presentation on long-term follow up from a study in

herniotomy surgeries which showed that, two years post-surgery, Adlea

treatment did not differ from placebo with regard to long-term

effects on sensory function in the surgical area.

* Preclinical studies suggesting that a single, clinically relevant

dose of Adlea does not have observable adverse effects on wound and

bone healing. A separate preclinical study demonstrated that a single

dose of Adlea caused a prolonged decrease in specific neuronal

markers and the TRPV1 receptor, suggestive of desensitization of the

nerve fibers, which gradually reversed several weeks following


Additional Development

-- Anesiva out-licensed worldwide rights to its NF-kappa B Decoy program

to Transcription Factor Therapeutics, Inc. Anesiva will receive an

upfront licensing fee, and will be entitled to receive milestone

payments totaling up to $114 million if two products are

commercialized. NF-kappa B is a protein implicated in autoimmune and

inflammatory disease processes, therapeutic areas outside Anesiva's

current focus on pain management.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company's first commercial product, Zingo(TM), is available in the U.S. for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. For full Zingo prescribing information and other information, visit An sNDA is under review at FDA to expand the Zingo label indication to include adults.

The next product in Anesiva's pipeline, Adlea(TM), is currently being evaluated in Phase 3 clinical trials for the management of acute pain following orthopedic surgeries. Adlea has been shown to reduce pain after only a single administration for up to weeks to months in multiple settings based on the results of several mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain.

Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward- looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: whether Zingo gains FDA approval in the adult indication, the degree to which Zingo gains market acceptance, and whether the Adlea clinical trials will be successful. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva's annual report on Form 10-K for the year ended December 31, 2007, and its most recent filing on Form 10-Q.

Anesiva, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

For the three months For the six months

ended June 30, ended June 30,

2008 2007 2008 2007

Contract revenues $302 $- $303 $-

Operating expenses:

Manufacturing start-up costs 1,125 - 1,125 -

Research and development 13,063 8,412 26,447 15,374

Sales, general and

administrative 7,914 6,246 16,371 12,000

Total operating expenses 22,102 14,658 43,943 27,374

Loss from operations (21,800) (14,658) (43,640) (27,374)

Interest expense and other income (111) 820 137 1,858

Loss before minority interest (21,911) (13,838) (43,503) (25,516)

Minority interest in loss of

variable interest entity 52 - 61 -

Net loss $(21,859) $(13,838) $(43,442) $(25,516)

Basic and diluted net loss per

common share $(0.54) $(0.51) $(1.08) $(0.93)

Weighted average shares used to

compute basic and diluted net

loss per common share 40,328 27,376 40,299 27,353

Anesiva, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

June 30, December 31,

2008 2007

(Unaudited) (Note)


Cash and cash equivalents $48,667 $90,840

Other current assets 4,082 2,225

Total current assets 52,749 93,065

Property and equipment, net 17,733 15,276

Other assets, non-current 1,466 1,395

Total assets $71,948 $109,736

Liabilities and stockholders' equity

Current liabilities $15,117 $12,175

Long term obligations 7,882 9,047

Minority interest 485 -

Total stockholders' equity 48,464 88,514

Total liabilities and stockholders' equity $71,948 $109,736

(Note): Derived from audited financial statements at that date.

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015 ... that management will participate in a fireside chat discussion ... New York . The discussion is ... Time. .  A replay will ... Contact:  Media Contact:McDavid Stilwell  , Julie NormartVP, Corporate ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... ... 2015 , ... The United States Golf Association (USGA) today announced Dr. Bruce ... Presented annually since 1961, the USGA Green Section Award recognizes an individual’s distinguished service ... , Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology in the ...
Breaking Biology Technology:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... Fingerprint Sensors - Technology and Patent Infringement Risk Analysis" ... --> --> Fingerprint sensors using capacitive ... The fingerprint sensor vendor Idex forecasts an increase of ... mobile devices and of the fingerprint sensor market between ...
(Date:11/20/2015)... November 20, 2015 NXTD ) ... on the growing mobile commerce market and creator of ... Pereira , was recently interviewed on The RedChip ... on this weekend on Bloomberg Europe , Bloomberg ... --> NXTD ) ("NXT-ID" or the "Company"), ...
(Date:11/19/2015)...  Based on its in-depth analysis of the biometric ... the 2015 Global Frost & Sullivan Award for Product ... this award to the company that has developed the ... the market it serves. The award recognizes the extent ... customer base demands, the overall impact it has in ...
Breaking Biology News(10 mins):